The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has today approved garadacimab (brand name Andembry) for patients aged 12 years and older with hereditary angioedema (HAE) to ...

The HAELO trial will assess the therapy’s safety and efficacy in 60 adult subjects with Type I or Type II HAE.

“We had no idea what it was,” says Wardman. She was terrified. The swollen hand of a patient with hereditary angioedema.Credit: HAE Australasia / Supplied As she hit puberty, the attacks ...

Australia’s Therapeutic Goods Administration (TGA) has approved CSL Ltd.’s Andembry (garadacimab) for preventing recurrent ...

Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but its ...

The allergy and immunology community mourns the loss of Marcus Maurer, MD, executive director of the Institute of Allergology ...

Learn more about whether Ionis Pharmaceuticals, Inc. or PTC Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Morgan Stanley lowered shares of Intellia Therapeutics (NASDAQ:NTLA – Free Report) from an overweight rating to an equal ...

Morgan Stanley (NYSE:MS) adjusted its stance on Intellia Therapeutics shares, downgrading the biotechnology company from Overweight to Equalweight. Accompanying this change, the firm also ...

The mainstay treatment for hereditary angioedema (HAE) is the use of on-demand therapies and long-term prophylaxis to achieve some measure of disease control, thereby alleviating some of the disease ...